Literature DB >> 30686687

Association between MTHFR 677C>T polymorphism and vascular complications in sickle cell disease: A meta-analysis.

B V K S Lakkakula1.   

Abstract

Sickle cell disease (SCD) is considered as a vascular disease due to its chronic vascular manifestations such as leg ulcers, priapism, acute chest syndrome (ACS), stroke, retinopathy, renal insufficiency, pulmonary hypertension, avascular necrosis of the femoral head (AVNF) and splenic infarction. Emerging evidence has shown that the MTHFR 677C>T variant allele is associated with vascular complications (VC) in patients with SCD; however, results from individual studies are inconclusive. The aim of this meta-analysis is to evaluate the association between the MTHFR 677C>T polymorphism and the susceptibility for VC in SCD patients. Articles published in English were collected from Medline, PubMed, Embase, and Web of Science databases. As a result, 11 studies in different populations including 614 SCD patients with VC, and 559 patients without VC were selected. Meta-analysis in fixed effect model showed that mutant genotypes (CT+TT vs. CC) of the MTHFR 677C>T polymorphism is associated with increased risk of vascular complication (OR=1.81, 95% CI=1.37-2.40, P<0.001). This study did not demonstrate publication bias or between-study heterogeneity. Our meta-analysis establishes that the MTHFR 677C>T polymorphism as a high-penetrant risk factor for VC in SCD patients. Further research is needed to support the clinical utility of MTHFR genetic testing for predicting VC in patients with sickle cell disease.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  C677T; Drépanocytose; MTHFR; Meta-analysis; Méta-analyse; Polymorphism; Polymorphisme; SCA; SCD; Sickle cell anemia

Mesh:

Substances:

Year:  2019        PMID: 30686687     DOI: 10.1016/j.tracli.2019.01.003

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  4 in total

Review 1.  Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.

Authors:  Henu Kumar Verma; Yashwant Kumar Ratre; L V K S Bhaskar; Raffaella Colombatti
Journal:  Ann Hematol       Date:  2021-01-04       Impact factor: 3.673

2.  Polymorphisms and avascular necrosis in patients with sickle cell disease - A systematic review.

Authors:  Márcio Passos Leandro; Natália Damasceno Almeida; Lara Santana Hocevar; Cloud Kennedy Couto de Sá; Amâncio José de Souza; Marcos Almeida Matos
Journal:  Rev Paul Pediatr       Date:  2022-05-11

3.  Association of the methylenetetrahydrofolate reductase (MTHFR) gene variant C677T with serum homocysteine levels and the severity of ischaemic stroke: a case-control study in the southwest of China.

Authors:  Lu-Wen Huang; Lin-Lin Li; Juan Li; Xiao-Rong Chen; Ming Yu
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

4.  Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease.

Authors:  Karina Tozatto-Maio; Robert Girot; Indou Deme Ly; Ana Cristina Silva Pinto; Vanderson Rocha; Francisco Fernandes; Ibrahima Diagne; Yahia Benzerara; Carla L Dinardo; Julia Pavan Soler; Simone Kashima; Itauá Leston Araujo; Chantal Kenzey; Guilherme H H Fonseca; Evandra S Rodrigues; Fernanda Volt; Luciana Jarduli; Annalisa Ruggeri; Christina Mariaselvam; Sandra F M Gualandro; Hanadi Rafii; Barbara Cappelli; Felipe Melo Nogueira; Graziana Maria Scigliuolo; Renato Luiz Guerino-Cunha; Kelen Cristina Ribeiro Malmegrim; Belinda P Simões; Eliane Gluckman; Ryad Tamouza
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.